Virgilant v. ABC Assets: $2.46M Default Judgment in Respiratory Device Patent Dispute
Virgilant Technologies secured a $2,461,250 default judgment against ABC Assets, Inc. in the District of Delaware after asserting US10019555B2, a patent covering interactive respiratory device usage tracking. The case, filed in February 2021 and resolved in August 2025, spanned over 1,600 days before concluding without a contested merits ruling — ABC Assets’ failure to defend drove the outcome.
Default judgment caps a 4.5-year patent fight over respiratory device tracking IP
Virgilant Technologies, Ltd. filed suit on February 10, 2021, in the U.S. District Court for the District of Delaware, asserting infringement of US10019555B2 against ABC Assets, Inc. and AptarGroup, Inc. The patent covers an interactive respiratory device usage tracking system — technology relevant to connected inhaler and respiratory adherence monitoring markets. Judge Maryellen Noreika presided over proceedings that extended across more than four and a half years.
The case terminated on August 13, 2025, through default judgment rather than a contested trial or settlement. The Court entered judgment exclusively against ABC Assets, Inc. — notably not AptarGroup, Inc. — awarding Virgilant $2,461,250 in damages plus post-judgment interest at 3.92% per annum from the judgment date. The basis of termination is recorded as ‘Default Judgment,’ indicating ABC Assets failed to appear or adequately defend, while the claims against AptarGroup appear to have proceeded on a separate track or resolved independently.
The duration of 1,645 days before default judgment is atypical and suggests the case involved protracted procedural history — possibly including contested motions or parallel proceedings involving AptarGroup — before ABC Assets ultimately defaulted. The public record is silent on any settlement with AptarGroup or on the specific infringing acts alleged. The damages figure of $2,461,250 reflects the Court’s quantification per its Memorandum Order (D.I. 85), though the methodology underlying that sum is not disclosed in the verdict text alone.
Filing to Default Judgment in 1645 days
1,645 days — well above median for D. Del. patent cases, suggesting extended procedural complexity before default.
Default judgment entered: what the $2.46M award means for both parties
Default judgment: liability by failure to defend
A default judgment is entered when a defendant fails to appear or respond adequately to a complaint. The court accepts the plaintiff’s well-pleaded allegations as true and determines the appropriate damages. Here, ABC Assets, Inc. did not mount a defense, allowing Virgilant to obtain judgment without a contested merits determination on infringement or validity. The Court’s Memorandum Order (D.I. 85) provides the quantification basis, though that reasoning is not publicly summarised in the verdict text.
No merits adjudicationVirgilant secures $2.46M award and enforceable judgment
Virgilant Technologies obtains a money judgment of $2,461,250 plus post-judgment interest at 3.92% — immediately enforceable against ABC Assets, Inc.’s assets. The patent, US10019555B2, was not subjected to a validity challenge through this proceeding, meaning it emerges from this case unchallenged in court. Virgilant retains full enforcement rights and may pursue additional defendants or licensees armed with this judgment as precedent of value.
Patent validity unchallengedABC Assets faces $2.46M liability with no appeal on the merits
ABC Assets, Inc. bears full liability for the judgment amount. Defendants who default retain the right to move to set aside a default judgment under Fed. R. Civ. P. 60(b), but must demonstrate excusable neglect, a meritorious defense, and absence of prejudice to plaintiff — a high bar. Separately, AptarGroup, Inc. was named as a co-defendant but is not mentioned in the default judgment, suggesting its posture in the case resolved differently, though the public record does not specify how.
Limited post-judgment remediesConnected inhaler IP enforcement risk heightened for the sector
US10019555B2 covering interactive respiratory device usage tracking remains valid and enforceable without any court-entered invalidity finding. Companies operating in connected inhaler, smart nebuliser, or respiratory adherence monitoring markets should treat this patent as an active enforcement asset. The $2.46M damages figure — obtained without contested damages discovery — may inform Virgilant’s future licensing demands across the sector. FTO analysis against this patent is advisable for any product involving device usage tracking.
Active enforcement riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Virgilant Technologies, Ltd. | Company | Connected respiratory device IP licensor — holder of US10019555B2 covering usage tracking systemsSearch in Eureka ↗ |
| Defendant | ABC Assets, Inc. | Company | ABC Assets, Inc. — defendant against whom default judgment was entered; AptarGroup, Inc. also named co-defendantSearch in Eureka ↗ |
| Co-Defendant | AptarGroup, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Aimee M. Czachorowski | Attorney | Counsel for Virgilant Technologies, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Ciro Carmine Poppiti , III | Attorney | Counsel for Virgilant Technologies, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Francis G.X. Pileggi | Attorney | Counsel for Virgilant Technologies, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Lewis Brisbois Bisgaard & Smith LLP | Law Firm | Representing Virgilant Technologies, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Poppiti Law, LLC | Law Firm | Representing Virgilant Technologies, Ltd.Search in Eureka ↗ |
| Defendant counsel | Andrew Hall Sauder | Attorney | Counsel for ABC Assets, Inc.Search in Eureka ↗ |
| Defendant counsel | Tyler J. Leavengood | Attorney | Counsel for ABC Assets, Inc.Search in Eureka ↗ |
| Defendant law firm | Dailey LLP | Law Firm | Representing ABC Assets, Inc.Search in Eureka ↗ |
| Defendant law firm | Potter Anderson & Corroon, LLP | Law Firm | Representing ABC Assets, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Maryellen Noreika | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The Court’s default judgment order (D.I. 85) awards $2,461,250 exclusively against ABC Assets, Inc. — the phrasing ‘as to Plaintiff’s claims’ suggests the full damages sought on the pleadings were granted without reduction through adversarial process. Notably, the order is silent on AptarGroup, Inc., implying that co-defendant’s exposure was resolved separately. Post-judgment interest at 3.92% accrues immediately, creating ongoing financial pressure on ABC Assets. Because no merits determination underlies this judgment, US10019555B2’s validity and claim scope remain judicially untested.
US10019555B2 — Interactive Respiratory Device Usage Tracking System
US10019555B2, filed under application number US14/518529, covers an interactive system for tracking respiratory device usage — technology that sits at the intersection of connected health devices and patient adherence monitoring. The patent likely describes hardware-software integration enabling real-time or logged data capture from inhalers, nebulisers, or similar respiratory apparatus, supporting clinical and commercial adherence programs. Its grant provides Virgilant with claims over a product category experiencing significant market expansion driven by digital therapeutics and remote patient monitoring trends.
From a competitive intelligence standpoint, US10019555B2 represents a strategically positioned asset in the growing connected inhaler and smart respiratory device market — a space attracting investment from pharmaceutical companies, medtech OEMs, and digital health platforms. AptarGroup, Inc.’s presence as a co-defendant is commercially significant: AptarGroup is a major supplier of drug delivery devices including inhaler components, suggesting the patent’s claims may have broad applicability across the respiratory delivery supply chain. Any competitor developing IoT-enabled respiratory adherence solutions should treat this patent as a live enforcement risk.
Should you run an FTO analysis against US10019555B2?
Any company developing, manufacturing, or commercialising connected respiratory devices — including smart inhalers, digital nebulisers, adherence tracking platforms, or patient monitoring systems that log device usage — should assess freedom to operate against US10019555B2. The patent is now backed by an enforceable damages judgment, and its claims have not been narrowed or invalidated through adversarial litigation. Pharmaceutical companies partnering with device OEMs on digital adherence programmes face particular exposure given the supply chain breadth suggested by AptarGroup’s co-defendant status.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of US10019555B2 against your product’s technical specifications, identify prior art potentially available for IPR or reexamination, and surface design-around options. Given that no Markman order was issued in this case, claim scope remains undefined by court construction — Eureka’s claim analysis tools can model likely interpretive outcomes and flag prosecution history estoppel risks before you engage counsel for a full FTO opinion.
Run a freedom-to-operate analysis on US10019555B2 to assess your product’s exposure
Run FTO in Eureka →Similar respiratory device and connected health patent cases in Delaware
Cases involving interactive connected health device patents litigated in the District of Delaware, including respiratory monitoring and digital adherence technology disputes.
What this case signals for the connected respiratory device IP landscape
A $2.46M default judgment on a respiratory tracking patent reinforces enforcement momentum in the connected health device sector.
Default judgments can set damages benchmarks even without merits findings
The $2,461,250 award was entered on Virgilant’s pleaded damages figure, not through contested expert testimony. In future licensing discussions or litigation against other parties, this judgment may serve as a reference point for royalty demands tied to US10019555B2 — even though it reflects a default rather than a fully litigated damages award.
AptarGroup’s divergent case path warrants close monitoring
AptarGroup, Inc. was named as a co-defendant but does not appear in the default judgment. This suggests either a separate resolution — through settlement, dismissal, or ongoing proceedings — or a different liability theory. Companies in the respiratory device space should monitor docket activity for any AptarGroup-specific outcome, which could affect the patent’s enforceability posture.
Virgilant v ABC — key questions answered
The District of Delaware entered default judgment in favour of Virgilant Technologies, Ltd. against ABC Assets, Inc. on August 13, 2025, awarding $2,461,250 plus post-judgment interest at 3.92% per annum. The judgment was entered pursuant to the Court’s Memorandum Order (D.I. 85). Co-defendant AptarGroup, Inc. is not referenced in the default judgment order.
Virgilant Technologies asserted US10019555B2, filed under application number US14/518529, covering an interactive respiratory device usage tracking system. The patent relates to connected health technology enabling monitoring and logging of respiratory device usage, relevant to smart inhaler and patient adherence applications.
Default judgment is entered when a defendant fails to appear or adequately respond to a complaint. The Court accepted Virgilant’s well-pleaded allegations and quantified damages via Memorandum Order (D.I. 85). No merits determination on infringement or patent validity was made. ABC Assets retains the right to seek relief under Fed. R. Civ. P. 60(b), though such motions face a high standard.
AptarGroup, Inc. was named as a co-defendant in Virgilant’s complaint but does not appear in the default judgment entered on August 13, 2025, which is directed solely against ABC Assets, Inc. The public record does not disclose how the claims against AptarGroup were resolved — possibilities include settlement, voluntary dismissal, or separate ongoing proceedings, but no order addressing AptarGroup’s disposition is reflected in the available case data.
The default judgment leaves US10019555B2 valid and judicially unchallenged, with an established damages benchmark of $2,461,250. Companies developing connected respiratory devices, smart inhalers, or usage adherence platforms should conduct FTO analysis against this patent. IPR petitionability should be evaluated, noting that the one-year time bar under 35 U.S.C. § 315(b) runs from the date a party is served with a complaint asserting the patent.
PatSnap Eureka searches patents and litigation data to answer instantly.